Showing results (2411-2420 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|June 3, 2010
Kit inhibitor APcK110 extends survival in an AML xenograft mouse modelStefan Faderl, Carlos Bueso-Ramos, Zhiming Liu, et al.
Investigational New Drugs|August 26, 2006
Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancerNeelima Denduluri, James J Lee, Janice Walshe, et al.
Investigational New Drugs|September 20, 2006
A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortiaGonzalo Gomez-Abuin, Eric Winquist, Walter M Stadler, et al.
Investigational New Drugs|October 31, 2006
The 4'-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cellsTracy A Brooks, Kieran L O'Loughlin, Hans Minderman, et al.
Investigational New Drugs|March 10, 2007
Antitumor activity of enzastaurin (LY317615.HCl) against human cancer cell lines and freshly explanted tumors investigated in in-vitro [corrected] soft-agar cloning experimentsAxel-Rainer Hanauske, Olaf Oberschmidt, Hartmut Hanauske-Abel, et al.
Investigational New Drugs|June 20, 2007
Phase II trial of alternating intravenous and oral vinorelbine in combination with cisplatin in advanced non-small cell lung cancerElisabetta Campagnoli, Isabella Garassino, Armando Santoro, et al.
Investigational New Drugs|June 15, 2007
A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancerSheri K Dennison, Samuel A Jacobs, John W Wilson, et al.
Investigational New Drugs|November 1, 1990
High versus low dose granisetron, a selective 5HT3 antagonist, for the prevention of chemotherapy-induced nausea and vomitingH C Falkson, C I Falkson, G Falkson
Investigational New Drugs|August 4, 2009
Phase II study of sunitinib malate in head and neck squamous cell carcinomaNicholas W Choong, Mark Kozloff, David Taber, et al.
Investigational New Drugs|September 29, 2009
TAE226-mediated inhibition of focal adhesion kinase interferes with tumor angiogenesis and vasculogenesisAlexander Schultze, Sebastian Decker, Jasmin Otten, et al.
Pageof 372